Peliglitazar (also known as BMS 426707-01), a dual α/γ peroxisome proliferator-activated receptor agonist, has been studied in phase I/II clinical trial in patients with type 2 diabetes mellitus. However, this study was discontinued.

Clothixamide is a dopamine antagonist. The compound was invented by Pfizer in the 1960s and is claimed to be useful for the chemotherapy of mental diseases and especially for the control of excited states. Also, clothixamide is claimed to have potent antiemetic properties.

Ritolukast (WY 48252) is an aerosol leukotriene D4 (LTD4) receptor antagonist. This orally administered drug was developed for use in treatment of asthma. Ritolukast was shown to prevent and reverse bronchoconstriction produced by aerosol LTD4 in guinea pigs. This drug also inhibited the synthesis of eicosanoids in rats and was therefore concluded to have modulatory effects on the arachidonic acid metabolism.

Climazolam is a benzodiazepine derivative, developed by Hoffman-LaRoche. It was used in veterinary for anesthetizing animals.

Inaperisone is a pyrrolidinopropiophenone derivative patented by Japanese pharmaceutical company Hokuriku Pharmaceutical Co. as muscle-relaxant and antispasmodic agent.

Naftoxate is an antimicotic agent. It is effective against both gram-positive and gram-negative bacteria as well as yeasts and other fungi in plant cell culture.

Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Brequinar had been in phase II clinical trials by Bristol-Myers Squibb for the treatment of cancer and transplant rejection. However, this research has been discontinued. Brequinar had been also in preclinical studys for the treatment of cytomegalovirus infections. However, this research has been discontinued.